USANA reports preliminary FY2022 net sales ~$995M, EPS ~$3.65; guides FY2023 net sales $850-950M, EPS $2.35-$3.30

USANA HEALTH SCIENCES INC

2022-FY EPS reported $3.59 revenue$998,601,000

Preliminary FY2022 net sales ~$995M, diluted EPS ~$3.65, above prior guidance of $955-975M and $3.15-$3.40.
Active Customers ~490,000 at year-end; incremental sales in China from COVID policy shift, but uncertainty persists.
Initial FY2023 guidance: net sales $850-950M, diluted EPS $2.35-$3.30, reflecting lower starting customer base and currency headwinds.
Company to report final Q4/FY2022 results on Feb 7, 2023; conference call Feb 8.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

USANA HEALTH SCIENCES INC reported the full fiscal year ended December 31, 2022 results: revenue approximately $995 million, EPS approximately $3.65.

Period: the full fiscal year ended December 31, 2022
Revenue: approximately $995 million
EPS: approximately $3.65
Result: preliminary results

Exact text from the filing

The Company currently anticipates fiscal year 2022 net sales of approximately $995 million and diluted earnings per share of approximately $3.65.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

USANA HEALTH SCIENCES INC reported the fiscal year ending December 30, 2023 results: revenue $850 - $950 million, EPS $2.35 - $3.30. Guidance initiated.

Period: the fiscal year ending December 30, 2023
Revenue: $850 - $950 million
EPS: $2.35 - $3.30
Guidance: initiated
Result: guidance update

Exact text from the filing

Initial Fiscal Year 2023 Guidance Consolidated Net Sales $850 - $950 million Diluted EPS $2.35 - $3.30

View on SEC.gov

Browse all earnings releases →

USANA HEALTH SCIENCES INC filing history →

Source: SEC EDGAR

accession 0001157523-23-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.